269 related articles for article (PubMed ID: 32178280)
1. Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes.
Xian J; Owusu Obeng E; Ratti S; Rusciano I; Marvi MV; Fazio A; De Stefano A; Mongiorgi S; Cappellini A; Ramazzotti G; Manzoli L; Cocco L; Follo MY
Cells; 2020 Mar; 9(3):. PubMed ID: 32178280
[TBL] [Abstract][Full Text] [Related]
2. Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes.
Mongiorgi S; Finelli C; Yang YR; Clissa C; McCubrey JA; Billi AM; Manzoli L; Suh PG; Cocco L; Follo MY
Expert Opin Ther Targets; 2016 Jun; 20(6):677-87. PubMed ID: 26610046
[TBL] [Abstract][Full Text] [Related]
3. Nuclear inositide signaling in myelodysplastic syndromes.
Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
[TBL] [Abstract][Full Text] [Related]
4. Advances in MDS/AML and inositide signalling.
De Stefano A; Marvi MV; Fazio A; McCubrey JA; Suh PG; Ratti S; Ramazzotti G; Manzoli L; Cocco L; Follo MY
Adv Biol Regul; 2023 Jan; 87():100955. PubMed ID: 36706610
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Inositide Signaling Via Phospholipase C.
Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
[TBL] [Abstract][Full Text] [Related]
6. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.
Follo MY; Mongiorgi S; Finelli C; Piazzi M; Faenza I; Ramazzotti G; Santi P; McCubrey JA; Martelli AM; Cocco L
Curr Pharm Des; 2012; 18(13):1751-4. PubMed ID: 22352752
[TBL] [Abstract][Full Text] [Related]
7. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
8. Nuclear phosphoinositides: location, regulation and function.
Fiume R; Keune WJ; Faenza I; Bultsma Y; Ramazzotti G; Jones DR; Martelli AM; Somner L; Follo MY; Divecha N; Cocco L
Subcell Biochem; 2012; 59():335-61. PubMed ID: 22374096
[TBL] [Abstract][Full Text] [Related]
9. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
10. Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia.
Ratti S; Mongiorgi S; Rusciano I; Manzoli L; Follo MY
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118649. PubMed ID: 31954103
[TBL] [Abstract][Full Text] [Related]
11. Nuclear PI-PLC β1 and Myelodysplastic syndromes: from bench to clinics.
Mongiorgi S; Follo MY; Clissa C; Giardino R; Fini M; Manzoli L; Ramazzotti G; Fiume R; Finelli C; Cocco L
Curr Top Microbiol Immunol; 2012; 362():235-45. PubMed ID: 23086421
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia.
Parisi S; Finelli C; Fazio A; De Stefano A; Mongiorgi S; Ratti S; Cappellini A; Billi AM; Cocco L; Follo MY; Manzoli L
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467674
[TBL] [Abstract][Full Text] [Related]
13. The physiology and pathology of inositide signaling in the nucleus.
Ramazzotti G; Faenza I; Fiume R; Matteucci A; Piazzi M; Follo MY; Cocco L
J Cell Physiol; 2011 Jan; 226(1):14-20. PubMed ID: 20658523
[TBL] [Abstract][Full Text] [Related]
14. Nuclear PI-PLCβ1: an appraisal on targets and pathology.
Follo MY; Faenza I; Piazzi M; Blalock WL; Manzoli L; McCubrey JA; Cocco L
Adv Biol Regul; 2014 Jan; 54():2-11. PubMed ID: 24296032
[TBL] [Abstract][Full Text] [Related]
15. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
[TBL] [Abstract][Full Text] [Related]
16. Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy.
Manzoli L; Mongiorgi S; Clissa C; Finelli C; Billi AM; Poli A; Quaranta M; Cocco L; Follo MY
Mini Rev Med Chem; 2014 Oct; ():. PubMed ID: 25307310
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
[TBL] [Abstract][Full Text] [Related]
18. Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells.
Cocco L; Follo MY; Faenza I; Bavelloni A; Billi AM; Martelli AM; Manzoli L
Adv Enzyme Regul; 2007; 47():2-9. PubMed ID: 17335878
[No Abstract] [Full Text] [Related]
19. Inositide-Dependent Nuclear Signalling in Health and Disease.
Follo MY; Ratti S; Manzoli L; Ramazzotti G; Faenza I; Fiume R; Mongiorgi S; Suh PG; McCubrey JA; Cocco L
Handb Exp Pharmacol; 2020; 259():291-308. PubMed ID: 31889219
[TBL] [Abstract][Full Text] [Related]
20. Nuclear inositides: facts and perspectives.
Martelli AM; Manzoli L; Cocco L
Pharmacol Ther; 2004 Jan; 101(1):47-64. PubMed ID: 14729392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
